March 22, 2000

IMPORTANT DRUG WARNING
PRODUCT WITHDRAWAL

Dear Pharmacist:

Following discussions with the U.S. Food and Drug Administration, Warner-Lambert Company has voluntarily discontinued the sale and distribution of Rezulin® (troglitazone) Tablets, its therapy for the treatment of type 2 diabetes. We have attached to this letter the Company's and the FDA's March 21, 2000 press releases announcing this action.

Concurrent with this letter, we are notifying physicians of the withdrawal.

Effective immediately, please do not dispense any further prescriptions for Rezulin®. Patients presenting prescriptions for Rezulin® should be instructed to consult with their physicians regarding alternative therapies as soon as possible.

Warner-Lambert has discontinued its distribution of Rezulin® and will be taking steps to arrange for wholesale and pharmacy returns of all existing stocks to the Company. Warner-Lambert will reimburse patients for their out-of-pocket expenses for unused supplies of Rezulin®. Patients having questions regarding this procedure may call 1-877-798-7398 for instructions.

You will be contacted shortly regarding procedures for return of and credit for unused stocks. Should you have any question in the interim, please call our Medical Affairs Department at 1-800-223-0432 or contact a local Parke-Davis or Sankyo Parke Davis representative.

Sincerely,

[Signature]

William R. Sigmund II, M.D., M.H.S., F.A.C.C.
Vice President, Medical and Scientific Affairs